“This program was helpful in reviewing the latest clinical data while intersecting it with appropriate utilization management to promote appropriate and timely patient access.”

Bispecifics are more than just new drugs—they represent an entirely new treatment modality. By leveraging our collective and expanding experience, we can better define best practices that support their access and use across all settings, including inpatient, outpatient, and community oncology.